Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 247 articles:
HTML format
Text format



Single Articles


    October 2019
  1. NAKAO S, Yamaguchi K, Sakamoto S, Horimasu Y, et al
    Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
    Anticancer Res. 2019;39:5725-5731.
    PubMed     Text format     Abstract available


  2. NASU S, Okamoto N, Suzuki H, Shiroyama T, et al
    Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer.
    Anticancer Res. 2019;39:5683-5688.
    PubMed     Text format     Abstract available


  3. ZHANG Q, Song Y, Cheng X, Xu Z, et al
    Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
    Anticancer Res. 2019;39:5461-5471.
    PubMed     Text format     Abstract available


  4. CHEN GL, Wang SC, Huang WC, Chang WS, et al
    The Association of MMP-11 Promoter Polymorphisms With Susceptibility to Lung Cancer in Taiwan.
    Anticancer Res. 2019;39:5375-5380.
    PubMed     Text format     Abstract available


  5. NAKANISHI K, Sakakura N, Matsui T, Ueno H, et al
    Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2019;39:5789-5795.
    PubMed     Text format     Abstract available


  6. REYNEL M, Villegas Y, Kiene H, Werthmann PG, et al
    Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion.
    Anticancer Res. 2019;39:5597-5604.
    PubMed     Text format     Abstract available


  7. ALTURKISTANI A, Ghonem N, Power-Charnitsky VA, Pino-Figueroa A, et al
    Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.
    Anticancer Res. 2019;39:5297-5310.
    PubMed     Text format     Abstract available


    September 2019
  8. GE H, Cheng N, Xu X, Yang Z, et al
    AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line.
    Anticancer Res. 2019;39:4637-4642.
    PubMed     Text format     Abstract available


  9. BUENTZEL J, Heinz J, Bleckmann A, Bauer C, et al
    Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis.
    Anticancer Res. 2019;39:4603-4612.
    PubMed     Text format     Abstract available


  10. FONTANA V, Pistillo MP, Vigani A, Canessa PA, et al
    Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Anticancer Res. 2019;39:5219-5223.
    PubMed     Text format     Abstract available


  11. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Text format     Abstract available


  12. KASMANN L, Taugner J, Eze C, Roengvoraphoj O, et al
    Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
    Anticancer Res. 2019;39:5077-5081.
    PubMed     Text format     Abstract available


  13. HARADA D, Takata K, Mori S, Kozuki T, et al
    Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Anticancer Res. 2019;39:4987-4993.
    PubMed     Text format     Abstract available


  14. KIYUNA T, Tome Y, Miyake K, Murakami T, et al
    Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2019;39:4775-4779.
    PubMed     Text format     Abstract available


    August 2019
  15. KOTSANTIS I, Economopoulou P, Psyrri A, Maratou E, et al
    Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:4185-4190.
    PubMed     Text format     Abstract available


  16. MORISAKI T, Kubo M, Umebayashi M, Yuan Y, et al
    Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy.
    Anticancer Res. 2019;39:4517-4523.
    PubMed     Text format     Abstract available


  17. CORTINOVIS D, Chiari R, Catino A, Grossi F, et al
    Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
    Anticancer Res. 2019;39:4265-4271.
    PubMed     Text format     Abstract available


  18. UDA NR, Stenner F, Seibert V, Herzig P, et al
    Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.
    Anticancer Res. 2019;39:4117-4128.
    PubMed     Text format     Abstract available


  19. YOON SN, Park JH, Lwin TM, Miyake K, et al
    Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis.
    Anticancer Res. 2019;39:4065-4071.
    PubMed     Text format     Abstract available


    July 2019
  20. GIULIANI J, Bonetti A
    Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.
    Anticancer Res. 2019;39:3961-3965.
    PubMed     Text format     Abstract available


  21. FUJITA K, Uchida N, Yamamoto Y, Kanai O, et al
    Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
    Anticancer Res. 2019;39:3917-3921.
    PubMed     Text format     Abstract available


  22. DRAG-ZALESINSKA M, Saczko J, Choromanska A, Szewczyk A, et al
    Cisplatin and Vinorelbine -Mediated Electrochemotherapeutic Approach Against Multidrug Resistant Small Cell Lung Cancer (H69AR) In Vitro.
    Anticancer Res. 2019;39:3711-3718.
    PubMed     Text format     Abstract available


  23. TAMIYA M, Tamiya A, Suzuki H, Moriizumi K, et al
    Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Anticancer Res. 2019;39:3923-3929.
    PubMed     Text format     Abstract available


  24. GEROGIANNI I, Pitaraki E, Jagirdar RM, Kouliou O, et al
    2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Anticancer Res. 2019;39:3809-3814.
    PubMed     Text format     Abstract available


  25. RODRIGUEZ-CORDOVA RJ, Gutierrez-Valenzuela CA, Bojang P, Esquivel R, et al
    Differential Response of BEAS-2B and H-441 Cells to Methylene Blue Photoactivation.
    Anticancer Res. 2019;39:3739-3744.
    PubMed     Text format     Abstract available


    June 2019
  26. CHASZCZEWSKA-MARKOWSKA M, Kosacka M, Chryplewicz A, Dyla T, et al
    ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population.
    Anticancer Res. 2019;39:3269-3272.
    PubMed     Text format     Abstract available


  27. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States.
    Anticancer Res. 2019;39:3137-3140.
    PubMed     Text format     Abstract available


  28. WOUTERS A, Durieux V, Kolivras A, Meert AP, et al
    Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review.
    Anticancer Res. 2019;39:3003-3008.
    PubMed     Text format     Abstract available


  29. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer.
    Anticancer Res. 2019;39:2957-2962.
    PubMed     Text format     Abstract available


  30. HU M, Tang Y, Long G, Zhang D, et al
    Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma.
    Anticancer Res. 2019;39:3197-3201.
    PubMed     Text format     Abstract available


    May 2019
  31. KAWACHI H, Fujimoto D, Yamashita D, Fukuoka J, et al
    Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
    Anticancer Res. 2019;39:2561-2567.
    PubMed     Text format     Abstract available


  32. KAIRA K, Imai H, Souma R, Sakurai R, et al
    An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:2483-2491.
    PubMed     Text format     Abstract available


  33. ERCAN S, Arinc S, Yilmaz SG, Altunok C, et al
    Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:2437-2441.
    PubMed     Text format     Abstract available


  34. KINOSHITA F, Toyokawa G, Matsubara T, Kozuma Y, et al
    Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.
    Anticancer Res. 2019;39:2665-2670.
    PubMed     Text format     Abstract available


  35. LINDBLOM EK, Dasu A, Toma-Dasu I
    Hypoxia Induced by Vascular Damage at High Doses Could Compromise the Outcome of Radiotherapy.
    Anticancer Res. 2019;39:2337-2340.
    PubMed     Text format     Abstract available


    April 2019
  36. SHINOHARA S, Otsuki R, Onitsuka T, Machida K, et al
    Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection.
    Anticancer Res. 2019;39:2193-2198.
    PubMed     Text format     Abstract available


  37. TAKADA K, Shimokawa M, Akamine T, Ono Y, et al
    Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1987-1996.
    PubMed     Text format     Abstract available


  38. CHECK JH, Check D, Poretta T
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Anticancer Res. 2019;39:1923-1926.
    PubMed     Text format     Abstract available


  39. KURIHARA E, Shien K, Torigoe H, Takeda T, et al
    Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1767-1775.
    PubMed     Text format     Abstract available


  40. YAN L, Sundaram S, Mehus AA, Picklo MJ, et al
    Time-restricted Feeding Attenuates High-fat Diet-enhanced Spontaneous Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1739-1748.
    PubMed     Text format     Abstract available


  41. SUNDARAM S, Yan L
    Adipose-specific Monocyte Chemotactic Protein-1 Deficiency Reduces Pulmonary Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1729-1738.
    PubMed     Text format     Abstract available


    March 2019

  42. Oxford Case Histories in Lung Cancer.
    Anticancer Res. 2019;39:1633.
    PubMed     Text format    


  43. NAKASHIMA K, Akamatsu H, Murakami H, Niwa T, et al
    Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1463-1468.
    PubMed     Text format     Abstract available


  44. KASAHARA N, Sunaga N, Tsukagoshi Y, Miura Y, et al
    Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.
    Anticancer Res. 2019;39:1455-1461.
    PubMed     Text format     Abstract available


  45. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Text format     Abstract available


  46. YASUKAWA M, Ohbayashi C, Kawaguchi T, Kawai N, et al
    Analysis of Histological Grade in Resected Lung-invasive Adenocarcinoma.
    Anticancer Res. 2019;39:1491-1500.
    PubMed     Text format     Abstract available


  47. CHO BC, DE Pas T, Kalofonos H, Wang Q, et al
    Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.
    Anticancer Res. 2019;39:1403-1409.
    PubMed     Text format     Abstract available


  48. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
    Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
    Anticancer Res. 2019;39:1343-1346.
    PubMed     Text format     Abstract available


  49. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Text format     Abstract available


  50. ONISHI H, Yamasaki A, Nakamura K, Ichimiya S, et al
    Liprin-alpha4 as a New Therapeutic Target for SCLC as an Upstream Mediator of HIF1alpha.
    Anticancer Res. 2019;39:1179-1184.
    PubMed     Text format     Abstract available


    February 2019
  51. SARUWATARI K, Ikeda T, Saeki S, Shingu N, et al
    Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Anticancer Res. 2019;39:923-931.
    PubMed     Text format     Abstract available


  52. PARIKH AB, Hammons L, Gomez JE
    Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review.
    Anticancer Res. 2019;39:897-902.
    PubMed     Text format     Abstract available


  53. KATSURADA M, Nagano T, Tachihara M, Kiriu T, et al
    Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:815-825.
    PubMed     Text format     Abstract available


  54. KUBO N, Harada T, Shiraishi Y, Nosaki K, et al
    Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:671-677.
    PubMed     Text format     Abstract available


  55. AKSORN N, Chanvorachote P
    Integrin as a Molecular Target for Anti-cancer Approaches in Lung Cancer.
    Anticancer Res. 2019;39:541-548.
    PubMed     Text format     Abstract available


  56. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
    Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
    Anticancer Res. 2019;39:1067-1072.
    PubMed     Text format     Abstract available


  57. SALO SAS, Ilonen I, Laaksonen S, Myllarniemi M, et al
    Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
    Anticancer Res. 2019;39:839-845.
    PubMed     Text format     Abstract available


  58. SUKARI A, Nagasaka M, Alhasan R, Patel D, et al
    Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Anticancer Res. 2019;39:781-790.
    PubMed     Text format     Abstract available


  59. NAKAYAMA K, Seike M, Noro R, Takeuchi S, et al
    Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
    Anticancer Res. 2019;39:627-633.
    PubMed     Text format     Abstract available


    January 2019
  60. WADA K, Kishi N, Kanayama N, Hirata T, et al
    Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy.
    Anticancer Res. 2019;39:491-497.
    PubMed     Text format     Abstract available


  61. KUO WI, Cheng KH, Chang YJ, Wu TT, et al
    Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts.
    Anticancer Res. 2019;39:183-190.
    PubMed     Text format     Abstract available


  62. KAIRA K, Kamiyoshihara M, Kawashima O, Endoh H, et al
    Prognostic Impact of beta2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2019;39:395-403.
    PubMed     Text format     Abstract available


  63. CHU CN, Wu KC, Chung WS, Zheng LC, et al
    Etomidate Suppresses Invasion and Migration of Human A549 Lung Adenocarcinoma Cells.
    Anticancer Res. 2019;39:215-223.
    PubMed     Text format     Abstract available


    December 2018
  64. FUJIMOTO D, Yamashita D, Fukuoka J, Kitamura Y, et al
    Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Anticancer Res. 2018;38:6891-6895.
    PubMed     Text format     Abstract available


  65. SVATON M, Zemanova M, Skrickova J, Jakubikova L, et al
    Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:6771-6782.
    PubMed     Text format     Abstract available


  66. TAMIYA H, Mitani A, Saito A, Ishimori T, et al
    Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion.
    Anticancer Res. 2018;38:6707-6714.
    PubMed     Text format     Abstract available


    November 2018
  67. AKAIKE K, Saruwatari K, Okabayashi H, Hamada S, et al
    Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.
    Anticancer Res. 2018;38:6543-6550.
    PubMed     Text format     Abstract available


  68. WU MF, Wang YC, Li HT, Chen WC, et al
    The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer.
    Anticancer Res. 2018;38:6321-6327.
    PubMed     Text format     Abstract available


  69. MOENG S, Seo HA, Hwang CY, Cipolla GA, et al
    MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide.
    Anticancer Res. 2018;38:6309-6316.
    PubMed     Text format     Abstract available


  70. LIU KH, Tsai YT, Chin SY, Lee WR, et al
    Hypoxia Stimulates the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear beta-Catenin.
    Anticancer Res. 2018;38:6299-6308.
    PubMed     Text format     Abstract available


  71. PHIBOONCHAIYANAN PP, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells via p53 Activation and Down-regulation of Survivin.
    Anticancer Res. 2018;38:6281-6290.
    PubMed     Text format     Abstract available


    October 2018
  72. WADA K, Kishi N, Kanayama N, Hirata T, et al
    Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.
    Anticancer Res. 2018;38:5951-5958.
    PubMed     Text format     Abstract available


  73. TAKAMORI S, Takada K, Azuma K, Jogo Y, et al
    Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Anticancer Res. 2018;38:5903-5907.
    PubMed     Text format     Abstract available


  74. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Text format     Abstract available


  75. CHEN GL, Shen TC, Chang WS, Tsai CW, et al
    The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility.
    Anticancer Res. 2018;38:5671-5677.
    PubMed     Text format     Abstract available


  76. YOUSSEF O, Knuuttila A, Piirila P, Bohling T, et al
    Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Anticancer Res. 2018;38:5627-5634.
    PubMed     Text format     Abstract available


  77. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  78. YOON N, Kim J, Maeng LS, Ahn JH, et al
    Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:6003-6008.
    PubMed     Text format     Abstract available


  79. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Text format     Abstract available


    September 2018
  80. TAKEUCHI A, Oguri T, Yamashita Y, Sone K, et al
    TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5489-5495.
    PubMed     Text format     Abstract available


  81. EZE C, Roengvoraphoj O, Dantes M, Abdo R, et al
    Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey.
    Anticancer Res. 2018;38:5261-5265.
    PubMed     Text format     Abstract available


  82. WU JY, Lin SS, Hsu FT, Chung JG, et al
    Fluoxetine Inhibits DNA Repair and NF-kB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5201-5210.
    PubMed     Text format     Abstract available


  83. HUANG YP, Jiang YW, Chen HY, Hsiao YT, et al
    Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:5165-5176.
    PubMed     Text format     Abstract available


  84. KURAMOTO K, Yamamoto M, Suzuki S, Sanomachi T, et al
    AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes.
    Anticancer Res. 2018;38:5093-5099.
    PubMed     Text format     Abstract available


  85. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:5057-5065.
    PubMed     Text format     Abstract available


  86. HAKOZAKI M, Tamura H, Dobashi Y, Yoshida A, et al
    Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination.
    Anticancer Res. 2018;38:5035-5042.
    PubMed     Text format     Abstract available


  87. RONCHI L, Buwenge M, Cortesi A, Ammendolia I, et al
    Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma.
    Anticancer Res. 2018;38:4977-4985.
    PubMed     Text format     Abstract available


  88. MILLETT RL, Elkon JM, Tabbara IA
    Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4969-4975.
    PubMed     Text format     Abstract available


  89. MIYAZAKI K, Tamura T, Kaburagi T, Saito K, et al
    Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation.
    Anticancer Res. 2018;38:5409-5415.
    PubMed     Text format     Abstract available


  90. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Text format     Abstract available


  91. TAKADA K, Toyokawa G, Tagawa T, Shimokawa M, et al
    Radiological Features of IDO1(+)/PDL1(+) Lung Adenocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2018;38:5295-5303.
    PubMed     Text format     Abstract available


  92. FURUTA H, Uemura T, Yoshida T, Kobara M, et al
    Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.
    Anticancer Res. 2018;38:5231-5237.
    PubMed     Text format     Abstract available


    August 2018
  93. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Text format     Abstract available


  94. SHIMIZU K, Okita R, Saisho S, Maeda AI, et al
    Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4637-4644.
    PubMed     Text format     Abstract available


  95. ONISHI H, Ichimiya S, Yanai K, Umebayashi M, et al
    RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
    Anticancer Res. 2018;38:4543-4547.
    PubMed     Text format     Abstract available


  96. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:4525-4533.
    PubMed     Text format     Abstract available


  97. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Text format     Abstract available


  98. WATANABE S, Yamaguchi OU, Masumoto AI, Maeno Y, et al
    Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
    Anticancer Res. 2018;38:4699-4704.
    PubMed     Text format     Abstract available


    July 2018
  99. BAXA J, Matouskova T, Ludvik J, Sedlmair M, et al
    Single-source Dual-energy CT as a Part of (18)F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4131-4137.
    PubMed     Text format     Abstract available


  100. SCHMID S, Csanadi A, Kozhuharov N, Tchudjin M, et al
    CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3913-3918.
    PubMed     Text format     Abstract available


  101. MAIUTHED A, Chantarawong W, Chanvorachote P
    Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
    Anticancer Res. 2018;38:3797-3809.
    PubMed     Text format     Abstract available


  102. ARIMOTO A, Yamashita K, Hasegawa H, Sugita Y, et al
    Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.
    Anticancer Res. 2018;38:4333-4338.
    PubMed     Text format     Abstract available


  103. TUPY R, Mirka H, Mracek J, Priban V, et al
    Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4149-4152.
    PubMed     Text format     Abstract available


  104. USUDA K, Iwai S, Funasaki A, Sekimura A, et al
    Expression and Prognostic Impact of VEGF, CD31 and alphaSMA in Resected Primary Lung Cancers.
    Anticancer Res. 2018;38:4057-4063.
    PubMed     Text format     Abstract available


  105. BASSANELLI M, Sioletic S, Martini M, Giacinti S, et al
    Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Anticancer Res. 2018;38:3789-3796.
    PubMed     Text format     Abstract available


    June 2018
  106. TAKEOKA H, Yamada K, Naito Y, Matsuo N, et al
    Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Anticancer Res. 2018;38:3779-3784.
    PubMed     Text format     Abstract available


  107. SHOJI F, Yamazaki K, Miura N, Katsura M, et al
    Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3773-3778.
    PubMed     Text format     Abstract available


  108. SYRIGOS KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, et al
    Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.
    Anticancer Res. 2018;38:3735-3744.
    PubMed     Text format     Abstract available


  109. TAKAMORI S, Toyokawa G, Shimokawa M, Kinoshita F, et al
    Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Anticancer Res. 2018;38:3731-3734.
    PubMed     Text format     Abstract available


  110. TOYOKAWA G, Takada K, Tagawa T, Kinoshita F, et al
    Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:3707-3711.
    PubMed     Text format     Abstract available


  111. BANNA GL, Camerini A, Bronte G, Anile G, et al
    Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Anticancer Res. 2018;38:3689-3697.
    PubMed     Text format     Abstract available


  112. MATSUMOTO T, Hasebe T, Baba Y, Chosa K, et al
    Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3587-3592.
    PubMed     Text format     Abstract available


  113. RAUNGRUT P, Wongkotsila A, Champoochana N, Lirdprapamongkol K, et al
    Knockdown of 14-3-3gamma Suppresses Epithelial-Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:3507-3514.
    PubMed     Text format     Abstract available


  114. KOYI H, Branden E, Kasim I, Wilander E, et al
    Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3341-3346.
    PubMed     Text format     Abstract available


  115. LAI JZ, Lai HH, Cao D
    Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Anticancer Res. 2018;38:3757-3761.
    PubMed     Text format     Abstract available


  116. HAGI T, Nakamura T, Sugino Y, Matsubara T, et al
    Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?
    Anticancer Res. 2018;38:3635-3639.
    PubMed     Text format     Abstract available


  117. MASUHIRO K, Shiroyama T, Suzuki H, Takata SO, et al
    Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.
    Anticancer Res. 2018;38:3567-3571.
    PubMed     Text format     Abstract available


  118. KOMIYA K, Nakashima C, Nakamura T, Hirakawa H, et al
    Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
    Anticancer Res. 2018;38:3559-3566.
    PubMed     Text format     Abstract available


  119. LIN MX, Lin SH, Lin CC, Yang CC, et al
    In Vitro and In Vivo Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:3435-3445.
    PubMed     Text format     Abstract available


  120. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


    May 2018
  121. SHINOHARA S, Sugaya M, Onitsuka T, Machida K, et al
    Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
    Anticancer Res. 2018;38:3193-3198.
    PubMed     Text format     Abstract available


  122. KINOSHITA F, Toyokawa G, Tagawa T, Matsubara T, et al
    Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.
    Anticancer Res. 2018;38:2957-2960.
    PubMed     Text format     Abstract available


  123. ALMQUIST D, Khanal N, Smith L, Ganti AK, et al
    Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2018;38:2903-2907.
    PubMed     Text format     Abstract available


  124. LIAO TY, Liaw CC, Tsui KH, Juan YH, et al
    Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis.
    Anticancer Res. 2018;38:3187-3192.
    PubMed     Text format     Abstract available


  125. KABURAGI T, Kiyoshima M, Nawa T, Ichimura H, et al
    Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
    Anticancer Res. 2018;38:3145-3150.
    PubMed     Text format     Abstract available


  126. KAWAGUCHI Y, Okano T, Kakihana M, Kajiwara N, et al
    Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3127-3132.
    PubMed     Text format     Abstract available


  127. TANAKA K, Toyokawa G, Tagawa T, Ijichi K, et al
    Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.
    Anticancer Res. 2018;38:3115-3118.
    PubMed     Text format     Abstract available


  128. OHNO T, Kubouchi Y, Wakahara M, Nosaka K, et al
    Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3001-3007.
    PubMed     Text format     Abstract available


    April 2018
  129. TAKEMURA Y, Chihara Y, Morimoto Y, Tanimura K, et al
    Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2385-2390.
    PubMed     Text format     Abstract available


  130. LUND-IVERSEN M, Scott H, Strom EH, Theiss N, et al
    Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2261-2269.
    PubMed     Text format     Abstract available


  131. VO VTA, Choi JW, Phan ANH, Hua TNM, et al
    TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:2187-2193.
    PubMed     Text format     Abstract available


  132. CHEN WT, Chen YK, Lin SS, Hsu FT, et al
    Hyperforin Suppresses Tumor Growth and NF-kappaB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2161-2167.
    PubMed     Text format     Abstract available


  133. BIANCONI F, Fravolini ML, Bello-Cerezo R, Minestrini M, et al
    Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2155-2160.
    PubMed     Text format     Abstract available


  134. HSIA TC, Huang YP, Jiang YW, Chen HY, et al
    Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:2137-2147.
    PubMed     Text format     Abstract available


  135. KANAJI N, Yokohira M, Watanabe N, Kadowaki N, et al
    Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype.
    Anticancer Res. 2018;38:2007-2014.
    PubMed     Text format     Abstract available


  136. MATSUMOTO N, Kumasaka A, Ando T, Komiyama K, et al
    Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method.
    Anticancer Res. 2018;38:2093-2099.
    PubMed     Text format     Abstract available


  137. RZECHONEK A, Grzegrzolka J, Blasiak P, Ornat M, et al
    Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:1987-1991.
    PubMed     Text format     Abstract available


  138. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Text format     Abstract available


    March 2018
  139. TOYOKAWA G, Yamada Y, Tagawa T, Kinoshita F, et al
    High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:1821-1825.
    PubMed     Text format     Abstract available


  140. NASU S, Suzuki H, Shiroyama T, Tanaka A, et al
    Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
    Anticancer Res. 2018;38:1783-1788.
    PubMed     Text format     Abstract available


  141. MATSUBARA T, Toyokawa G, Kinoshita F, Haratake N, et al
    Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors.
    Anticancer Res. 2018;38:1715-1719.
    PubMed     Text format     Abstract available


  142. SATO Y, Fujimoto D, Uehara K, Kawachi H, et al
    Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
    Anticancer Res. 2018;38:1401-1405.
    PubMed     Text format     Abstract available


    February 2018
  143. KATO Y, Kashima J, Watanabe K, Yomota M, et al
    Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:1077-1083.
    PubMed     Text format     Abstract available


  144. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Text format     Abstract available


  145. SAITOH JI, Shirai K, Abe T, Kubo N, et al
    A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:885-891.
    PubMed     Text format     Abstract available


  146. VALAN CD, Slagsvold JE, Halvorsen TO, Herje M, et al
    Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Anticancer Res. 2018;38:871-876.
    PubMed     Text format     Abstract available


  147. GLATZEL-PLUCINSKA N, Piotrowska A, Grzegrzolka J, Olbromski M, et al
    SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
    Anticancer Res. 2018;38:723-736.
    PubMed     Text format     Abstract available


  148. KOH YW, Park SY, Hyun SH, Lee SJ, et al
    Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:1067-1071.
    PubMed     Text format     Abstract available


  149. HIRAI F, Kinoshita I, Matsubara T, Haratake N, et al
    Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?
    Anticancer Res. 2018;38:1041-1045.
    PubMed     Text format     Abstract available


  150. ROBELLA M, Vaira M, Borsano A, Mossetti C, et al
    Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
    Anticancer Res. 2018;38:929-932.
    PubMed     Text format     Abstract available


  151. KOBAYASHI K, Seike M, Zou F, Noro R, et al
    Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
    Anticancer Res. 2018;38:753-762.
    PubMed     Text format     Abstract available


  152. AKIMOTO J, Nakayama M, Takagi S, Okano T, et al
    Improved In Vivo Subcutaneous Tumor Generation by Cancer Cell Sheet Transplantation.
    Anticancer Res. 2018;38:671-676.
    PubMed     Text format     Abstract available


  153. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  154. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:559-563.
    PubMed     Text format     Abstract available


  155. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:553-557.
    PubMed     Text format     Abstract available


  156. SLUGA R, VAN DEN Borne BEEM, Roepman P, Peters BJM, et al
    Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Anticancer Res. 2018;38:393-400.
    PubMed     Text format     Abstract available


  157. JUNG CY, Kim SY, Lee C
    Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:279-286.
    PubMed     Text format     Abstract available


  158. SHEN TC, Chang WS, Tsai CW, Chao CY, et al
    The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk.
    Anticancer Res. 2018;38:253-257.
    PubMed     Text format     Abstract available


  159. FANG T, Huang H, Li X, Liao J, et al
    Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:179-186.
    PubMed     Text format     Abstract available


  160. DAMASKOS C, Tomos I, Garmpis N, Karakatsani A, et al
    Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Anticancer Res. 2018;38:37-43.
    PubMed     Text format     Abstract available


  161. PRECIVAL C, Landy M, Poole C, Mullaney L, et al
    The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:7-14.
    PubMed     Text format     Abstract available


  162. HIGUCHI T, Yamamoto N, Hayashi K, Takeuchi A, et al
    The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma.
    Anticancer Res. 2018;38:577-582.
    PubMed     Text format     Abstract available


    December 2017
  163. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    Association Between PD-L1 Expression and Metabolic Activity on (18)F-FDG PET/CT in Patients with Small-sized Lung Cancer.
    Anticancer Res. 2017;37:7073-7082.
    PubMed     Text format     Abstract available


  164. SHOJI F, Matsubara T, Kozuma Y, Haratake N, et al
    Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6997-7003.
    PubMed     Text format     Abstract available


  165. KULDA V, Hrda K, Houdek Z, Dobra JK, et al
    Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6953-6958.
    PubMed     Text format     Abstract available


  166. ERBER R, Stohr R, Herlein S, Giedl C, et al
    Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6771-6778.
    PubMed     Text format     Abstract available


  167. MATSUBARA T, Toyokawa G, Yamada Y, Nabeshima K, et al
    A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
    Anticancer Res. 2017;37:6937-6941.
    PubMed     Text format     Abstract available


    November 2017
  168. OYA Y, Yoshida T, Kuroda H, Shimizu J, et al
    Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Anticancer Res. 2017;37:6477-6480.
    PubMed     Text format     Abstract available


  169. WILLS B, Cardona AF, Rojas L, Ruiz-Patino A, et al
    Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
    Anticancer Res. 2017;37:6429-6436.
    PubMed     Text format     Abstract available


  170. TUNGSUKRUTHAI S, Sritularak B, Chanvorachote P
    Cycloartobiloxanthone Inhibits Migration and Invasion of Lung Cancer Cells.
    Anticancer Res. 2017;37:6311-6319.
    PubMed     Text format     Abstract available


  171. PINKHIEN T, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Batatasin III Inhibits Migration of Human Lung Cancer Cells by Suppressing Epithelial to Mesenchymal Transition and FAK-AKT Signals.
    Anticancer Res. 2017;37:6281-6289.
    PubMed     Text format     Abstract available


  172. MAIUTHED A, Pinkhien T, Chamni S, Suwanborirux K, et al
    Apoptosis-inducing Effect of Hydroquinone 5-O-Cinnamoyl Ester Analog of Renieramycin M on Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:6259-6267.
    PubMed     Text format     Abstract available


  173. ICHIHARA H, Kuwabara K, Matsumoto Y
    Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo.
    Anticancer Res. 2017;37:6133-6139.
    PubMed     Text format     Abstract available


  174. MORIN C, Fortin S
    Docosahexaenoic Acid Monoglyceride Increases Carboplatin Activity in Lung Cancer Models by Targeting EGFR.
    Anticancer Res. 2017;37:6015-6023.
    PubMed     Text format     Abstract available


  175. FIALA O, Hosek P, Pesek M, Finek J, et al
    Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2017;37:6469-6476.
    PubMed     Text format     Abstract available


  176. MULLER L, Radtke A, Decker J, Koch M, et al
    The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
    Anticancer Res. 2017;37:6341-6345.
    PubMed     Text format     Abstract available


  177. SANOMACHI T, Suzuki S, Kuramoto K, Takeda H, et al
    Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
    Anticancer Res. 2017;37:6177-6188.
    PubMed     Text format     Abstract available


    October 2017
  178. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  179. TANIGUCHI Y, Tamiya A, Isa SI, Nakahama K, et al
    Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Anticancer Res. 2017;37:5857-5862.
    PubMed     Text format     Abstract available


  180. MATSUMOTO Y, Ohara S, Furukawa R, Usui K, et al
    The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis.
    Anticancer Res. 2017;37:5791-5795.
    PubMed     Text format     Abstract available


  181. TAKEUCHI A, Oguri T, Sone K, Ito K, et al
    Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Anticancer Res. 2017;37:5771-5776.
    PubMed     Text format     Abstract available


  182. SHIBA S, Saitoh JI, Irie D, Shirai K, et al
    Potential Pitfalls of a Fiducial Marker-matching Technique in Carbon-ion Radiotherapy for Lung Cancer.
    Anticancer Res. 2017;37:5673-5680.
    PubMed     Text format     Abstract available


  183. SUDO K, Sato K, Sakamoto S, Hasegawa Y, et al
    Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Anticancer Res. 2017;37:5565-5571.
    PubMed     Text format     Abstract available


  184. NAKAHAMA K, Isa SI, Tamiya A, Taniguchi Y, et al
    The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.
    Anticancer Res. 2017;37:5885-5891.
    PubMed     Text format     Abstract available


  185. HARATAKE N, Toyokawa G, Tagawa T, Kozuma Y, et al
    Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Anticancer Res. 2017;37:5713-5717.
    PubMed     Text format     Abstract available


  186. YASUKAWA M, Kawaguchi T, Kawai N, Tojo T, et al
    Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases.
    Anticancer Res. 2017;37:5573-5576.
    PubMed     Text format     Abstract available


    September 2017
  187. CELIK E, Semrau R, Baues C, Trommer-Nestler M, et al
    Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5285-5291.
    PubMed     Text format     Abstract available


  188. TAMIYA A, Tamiya M, Nakahama K, Taniguchi Y, et al
    Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5199-5205.
    PubMed     Text format     Abstract available


  189. SHINTANI T, Matsuo Y, Iizuka Y, Mitsuyoshi T, et al
    Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.
    Anticancer Res. 2017;37:5161-5167.
    PubMed     Text format     Abstract available


  190. SONE K, Oguri T, Ito K, Kitamura Y, et al
    Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:5125-5131.
    PubMed     Text format     Abstract available


  191. ONISHI H, Nakamura K, Nagai S, Yanai K, et al
    Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:4987-4992.
    PubMed     Text format     Abstract available


  192. HAMAGUCHI R, Okamoto T, Sato M, Hasegawa M, et al
    Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
    Anticancer Res. 2017;37:5141-5145.
    PubMed     Text format     Abstract available


  193. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Text format     Abstract available


  194. AMPIL F, Ellika S, Nanda A, Vora M, et al
    Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up.
    Anticancer Res. 2017;37:5113-5115.
    PubMed     Text format     Abstract available


  195. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Text format     Abstract available


  196. TAKENAKA T, Katayama M, Sugiyama A, Hagiwara M, et al
    Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
    Anticancer Res. 2017;37:4779-4788.
    PubMed     Text format     Abstract available


    August 2017
  197. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Text format     Abstract available


  198. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Text format     Abstract available


  199. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Text format     Abstract available


  200. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Text format     Abstract available


  201. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Text format     Abstract available


  202. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Text format     Abstract available


  203. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Text format     Abstract available


  204. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Text format     Abstract available


  205. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Text format     Abstract available


  206. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Text format     Abstract available


  207. ARIYASU R, Horiike A, Yoshizawa T, Dotsu Y, et al
    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
    Anticancer Res. 2017;37:4229-4232.
    PubMed     Text format     Abstract available


    July 2017
  208. YOTSUMOTO F, Fukagawa S, Miyata K, Nam SO, et al
    HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
    Anticancer Res. 2017;37:3825-3831.
    PubMed     Text format     Abstract available


  209. NAKAO M, Muramatsu H, Kagawa Y, Suzuki Y, et al
    Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
    Anticancer Res. 2017;37:3781-3786.
    PubMed     Text format     Abstract available


  210. BANNA GL, Parra HJS, Castaing M, Dieci MV, et al
    Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:3723-3728.
    PubMed     Text format     Abstract available


  211. SHEN TC, Hsia TC, Chao CY, Chen WC, et al
    The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer.
    Anticancer Res. 2017;37:3563-3567.
    PubMed     Text format     Abstract available


  212. PANCEWICZ-WOJTKIEWICZ J, Bernatowicz PL
    The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:3543-3546.
    PubMed     Text format     Abstract available


  213. OTSUKA T, Nojiri T, Minami S, Hosoda H, et al
    Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
    Anticancer Res. 2017;37:3505-3512.
    PubMed     Text format     Abstract available


  214. KOBAYASHI H, Hamasaki M, Morishita T, Inoue T, et al
    Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management.
    Anticancer Res. 2017;37:3969-3974.
    PubMed     Text format     Abstract available


  215. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available


    June 2017
  216. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.
    Anticancer Res. 2017;37:3307-3309.
    PubMed     Text format     Abstract available


  217. NAKAMICHI S, Seike M, Miyanaga A, Chiba M, et al
    RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients.
    Anticancer Res. 2017;37:3295-3299.
    PubMed     Text format     Abstract available


  218. MUTO S, Takagi H, Owada Y, Inoue T, et al
    Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:3169-3174.
    PubMed     Text format     Abstract available


  219. WANG W, Zhong W, Chen C, Meng Q, et al
    Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Anticancer Res. 2017;37:3151-3155.
    PubMed     Text format     Abstract available


  220. SINAGRA E, Raimondo D, Gallo E, Stella M, et al
    JC Virus and Lung Adenocarcinoma: Fact or Myth?
    Anticancer Res. 2017;37:3311-3314.
    PubMed     Text format     Abstract available


  221. KADERBHAI C, Richard C, Fumet JD, Aarnink A, et al
    Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
    Anticancer Res. 2017;37:3195-3200.
    PubMed     Text format     Abstract available


  222. MENCOBONI M, Filiberti RA, Taveggia P, Del Corso L, et al
    Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Anticancer Res. 2017;37:3189-3194.
    PubMed     Text format     Abstract available


  223. RIZZARDI C, Athanasakis E, Cammisuli F, Monego SD, et al
    Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy.
    Anticancer Res. 2017;37:3073-3083.
    PubMed     Text format     Abstract available


    May 2017
  224. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
    Anticancer Res. 2017;37:2721-2725.
    PubMed     Text format     Abstract available


  225. SHOJI F, Toyokawa G, Harada N, Itoh S, et al
    Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.
    Anticancer Res. 2017;37:2619-2623.
    PubMed     Text format     Abstract available


  226. JANSSEN S, VAN Oorschot B, Kasmann L, Schild SE, et al
    Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer.
    Anticancer Res. 2017;37:2537-2540.
    PubMed     Text format     Abstract available


  227. LIU D, Nakashima N, Nakano J, Tarumi S, et al
    Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Anticancer Res. 2017;37:2501-2507.
    PubMed     Text format     Abstract available


  228. DE MARINIS F, Bidoli P, Luciani A, Amoroso D, et al
    EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2457-2464.
    PubMed     Text format     Abstract available


  229. CHUANG CL, Wang CH, Hsu CH, Hsiao CL, et al
    Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer.
    Anticancer Res. 2017;37:2417-2423.
    PubMed     Text format     Abstract available


  230. LEE AY, Kim S, Lee S, Jiang HL, et al
    Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLA1 Lung Cancer Mice.
    Anticancer Res. 2017;37:2381-2386.
    PubMed     Text format     Abstract available


  231. MASAGO K, Fujita S, Hata A, Okuda C, et al
    PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2269-2274.
    PubMed     Text format     Abstract available


  232. HAO C, Cui Y, Hu MU, Zhi X, et al
    OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:2245-2254.
    PubMed     Text format     Abstract available


  233. TOKUNAGA S, Nagano T, Kobayashi K, Katsurada M, et al
    Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
    Anticancer Res. 2017;37:2225-2231.
    PubMed     Text format     Abstract available


  234. AKAMINE T, Toyokawa G, Matsubara T, Kozuma Y, et al
    Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease.
    Anticancer Res. 2017;37:2735-2742.
    PubMed     Text format     Abstract available


  235. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


  236. MIYATA T, Oyama T, Yoshimatsu T, Higa H, et al
    The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.
    Anticancer Res. 2017;37:2541-2547.
    PubMed     Text format     Abstract available


  237. DORE-SAVARD L, Chen Z, Winnard PT Jr, Krishnamachary B, et al
    Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Anticancer Res. 2017;37:2195-2200.
    PubMed     Text format     Abstract available


    April 2017
  238. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Text format     Abstract available


  239. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available


  240. KAITO D, Iihara H, Funaguchi N, Endo J, et al
    Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
    Anticancer Res. 2017;37:1965-1970.
    PubMed     Text format     Abstract available


  241. ABE S, Yamashita SI, Miyahara SO, Wakahara J, et al
    Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2017;37:1923-1929.
    PubMed     Text format     Abstract available


    March 2017
  242. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Text format     Abstract available


  243. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Text format     Abstract available


  244. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Text format     Abstract available


  245. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  246. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available


  247. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: